The emergence of strains of Plasmodium falciparum resistant to the commonly used antimalarials warrants the development of new antimalarial agents. The discovery of type II fatty acid synthase (FAS) in Plasmodium distinct from the FAS in its human host (type I FAS) opened up new avenues for the development of novel antimalarials. The process of fatty acid synthesis takes place by iterative elongation of butyryl-acyl carrier protein (butyryl-ACP) by two carbon units, with the successive action of four enzymes constituting the elongation module of FAS until the desired acyl length is obtained. The study of the fatty acid synthesis machinery of the parasite inside the red blood cell culture has always been a challenging task. Here, we report t...
Malaria, caused by the parasite Plasmodium, continues to exact high global morbidity and mortality r...
Malaria, one of the most problematic infectious diseases worldwide, is on the rise. The absence of a...
Triclosan is a potent inhibitor of FabI (enoyl-ACP reductase, where ACP stands for acyl carrier prot...
The emergence of strains of Plasmodium falciparum resistant to the commonly used antimalarials warra...
The emergence of strains of Plasmodium falciparum resistant to the commonly used antimalarials warra...
Malaria, one of the most problematic infectious diseases worldwide, is on the rise. The absence of a...
The human malaria parasite Plasmodium falciparum synthesizes fatty acids by using a type II synthase...
The emergence of drug-resistant forms of Plasmodium falciparum emphasizes the need to develop new an...
The emergence of drug-resistant forms of Plasmodium falciparum emphasizes the need to develop new an...
We have recently demonstrated that Plasmodium falciparum, unlike its human host, has the type II fat...
We have recently demonstrated that Plasmodium falciparum, unlike its human host, has the type II fat...
The fatty acid synthesis type II pathway has received considerable interest as a candidate therapeut...
SummaryThe fatty acid synthesis type II pathway has received considerable interest as a candidate th...
Malaria can be regarded as one of the world's worst health problems and its incidence is rising inex...
Triclosan is a potent inhibitor of FabI (enoyl-ACP reductase, whereACP stands for acyl carrier prote...
Malaria, caused by the parasite Plasmodium, continues to exact high global morbidity and mortality r...
Malaria, one of the most problematic infectious diseases worldwide, is on the rise. The absence of a...
Triclosan is a potent inhibitor of FabI (enoyl-ACP reductase, where ACP stands for acyl carrier prot...
The emergence of strains of Plasmodium falciparum resistant to the commonly used antimalarials warra...
The emergence of strains of Plasmodium falciparum resistant to the commonly used antimalarials warra...
Malaria, one of the most problematic infectious diseases worldwide, is on the rise. The absence of a...
The human malaria parasite Plasmodium falciparum synthesizes fatty acids by using a type II synthase...
The emergence of drug-resistant forms of Plasmodium falciparum emphasizes the need to develop new an...
The emergence of drug-resistant forms of Plasmodium falciparum emphasizes the need to develop new an...
We have recently demonstrated that Plasmodium falciparum, unlike its human host, has the type II fat...
We have recently demonstrated that Plasmodium falciparum, unlike its human host, has the type II fat...
The fatty acid synthesis type II pathway has received considerable interest as a candidate therapeut...
SummaryThe fatty acid synthesis type II pathway has received considerable interest as a candidate th...
Malaria can be regarded as one of the world's worst health problems and its incidence is rising inex...
Triclosan is a potent inhibitor of FabI (enoyl-ACP reductase, whereACP stands for acyl carrier prote...
Malaria, caused by the parasite Plasmodium, continues to exact high global morbidity and mortality r...
Malaria, one of the most problematic infectious diseases worldwide, is on the rise. The absence of a...
Triclosan is a potent inhibitor of FabI (enoyl-ACP reductase, where ACP stands for acyl carrier prot...